Elicio Therapeutics, Inc. · NASDAQ:ELTX
Elicio Therapeutics — Investor Presentation (January 2024)
24 slides from Elicio Therapeutics's investor presentation, January 2024
Slide 1: Targeting the Lymph Nodes to AMPlify Immunotherapy
Targeting the Lymph Nodes to AMPlify Immunotherapy January 2024
Slide 2: Disclaimers
Disclaimers Forward-Looking Statements This presentation contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, kno
Slide 3: Company Highlights
Company Highlights Clinical-stage biotech pioneering novel lymph node targeted cancer immunotherapies Novel Approach to • Amphiphile or “AMP” platform traffics payloads to lymph nodes to generate robust immune Immunotherapy responses ELI-002: A Unique • Designed to target 7 KRAS mutations that drive
Slide 4: Pipeline
Pipeline Innovative pipeline of cancer immunotherapies addressing critical unmet needs Candidate Target Indications Preclinical Phase 1 Phase 2 Phase 3 ELI-002 mKRAS PDAC, CRC PDAC PDAC ELI-007 mBRAF GI Tumors ELI-008 mTP53 GI Tumors Ongoing Planned CRC: colorectal carcinoma | PDAC: Pancreatic pancr
Slide 5: Elicio: Amplifying Immunotherapy
Elicio: Amplifying Immunotherapy
Slide 6: The AMP Platform
The AMP Platform Harnessing the untapped potential of the lymph nodes for immunotherapy Tissue Injection Site Targeting Immunity in the Lymph Nodes Blood Vessel • Most immune cells are located in lymph nodes, yet these critical sites are not engaged by conventional immunotherapies Blood Blood Circul
Slide 7: ELI-002 Composition
ELI-002 Composition Lymph node targeted therapeutic vaccine comprised of AMP-peptides and AMP-CpG G12X G13X D R V C S A D AMP-mKRAS X X Peptide Antigen ELI-002 • 2 or 7 AMP-peptides • CD8 and CD4 epitopes Albumin Binding Lipid for PEG Linker mKRAS Peptide Lymph Node Targeting O AMP-CpG NH Adjuvant O
Slide 8: Mechanism of Action
Mechanism of Action AMP immunotherapy generates an anti-tumor immune response via the lymph nodes Tissue Injection Site Lymph Node Tumor Amphiphiles Endogenous Albumin Albumin-bound Amphiphiles Albumin-bound Amphiphiles Antigen Presenting Cell T Cell 1 Subcutaneous 2 Albumin 3 Lymph node 4 Delivery
Slide 9: The mKRAS Opportunity
The mKRAS Opportunity ELI-002 targets the 7 most common KRAS mutations driving 25% of solid tumors Pancreatic Ductal Colorectal Non-Small Cell Other mKRAS Adenocarcinoma Cancer Lung Cancer Opportunities ELI-002 ELI-002 ELI-002 17% addressable addressable addressable Incidence: ~128k Incidence: ~192k
Slide 10: ELI-002's Differentiated Approach to mKRAS
ELI-002’s Differentiated Approach to mKRAS Early mKRAS-targeting efforts in the clinic, while promising, leave significant white space Small Molecules Directly Small Molecules Indirectly Vaccines Targeting Lymph Node Targeted Inhibiting Mutant KRAS Inhibiting Mutant KRAS Mutant KRAS Vaccine vs Mutan
Slide 11: ELI-002: Clinical Development Program
ELI-002: Clinical Development Program
Slide 12: ELI-002 At-a-Glance
ELI-002 At-a-Glance mKRAS immunotherapy eliciting strong T cell activity leveraging the AMP platform’s lymph node targeting design 2 Peptide (2P) & • 2P used in Phase 1 AMPLIFY-201 for clinical proof-of-concept while 7P CMC finalized 7 Peptide (7P) • Program now switches to full 7P formulation, to m
Slide 13: AMPLIFY-201 Study Overview
AMPLIFY-201 Study Overview Phase 1 dose-ranging study to assess safety and efficacy of ELI-002 2P as adjuvant treatment in patients who completed standard therapy and have molecular disease CLINICAL PROGRAM OVERVIEW: NCT04853017 Key Criteria Local Therapy Basket Trial Enrollment mKRAS G12D / R – a
Slide 14: AMPLIFY-201: Tumor Biomarker Responses
AMPLIFY-201: Tumor Biomarker Responses Robust responses observed across tumor types and KRAS mutations with ELI-002 monotherapy Tumor Biomarker Responses AMPLIFY-201 Waterfall Plot: Biomarker Reduction/Clearance Best Overall Biomarker Response 100 Cohort 1: 0.1 mg 75 Cohort 2: 0.5 mg • 24% of patien
Slide 15: AMPLIFY-201: 84% patients generated mKRAS specific T Cells
AMPLIFY-201: 84% patients generated mKRAS specific T Cells mKRAS T Cell Responses AMPLIFY-201 T Cell Fold-Changes by Dose Level Direct Ex Vivo T Cell Response Response per Dose Level • 84% of patients showed T cell responses 450 AMP-CpG ex vivo T cell Average 50 Dose response fold- Fold Change from
Slide 16: AMPLIFY-201: T Cell Fold-Change Predicts Tumor Biomarker Response
AMPLIFY-201: T Cell Fold-Change Predicts Tumor Biomarker Response All patients with T cell responses over median showed tumor biomarker response mKRAS T Cell Response Tumor Biomarker Response Best Overall Tumor Biomarker Response Clearance Reduction Non-Responder • Strength of T cell response to ELI
Slide 17: AMPLIFY-201: Majority of Above Median T Cell Responders Include CD4+ and CD8+
AMPLIFY-201: Majority of Above Median T Cell Responders Include CD4+ and CD8+ Above median mKRAS-specific T cell response correlates to improved clinical outcome mKRAS T Cell Response Clinical Response • Strength of T cell response to ELI-002 is correlated to tumor response and duration of ELI-002 a
Slide 18: AMPLIFY-201: Above Median T Cell Responders Median RFS Significantly Prolonged
AMPLIFY-201: Above Median T Cell Responders Median RFS Significantly Prolonged 86% reduction in the risk of progression or death in above median T cell responders mKRAS T Cell Response Clinical Response Relapse-free Survival ≥ Median T Cell Response (n = 13) • At a median follow up of 8.5 months, me
Slide 19: AMPLIFY-201: Safety & Tolerability
AMPLIFY-201: Safety & Tolerability ELI-002 was well tolerated at all dose levels, with no DLTs or SAEs Cohort 1 Cohort 2 Cohort 3 Cohort 4 Cohort 5 Overall ELI-002 Safety / Tolerability (0.1 mg) (0.5 mg) (2.5 mg) (5.0 mg) (10.0 mg) n=3 n=6 n=5 n=5 n=6 n = 25 Adverse Event Terma Patients with Any • N
Slide 20: AMPLIFY-201: T Cell Tumor Infiltration
AMPLIFY-201: T Cell Tumor Infiltration Preliminary clinical evidence shows dense T cell tumor infiltration following ELI-002 therapy T Cell Tumor Infiltration Tumor Biopsy: CD3 Immunohistochemistry • 76 T cells/hpf at time of progression, 29x the expected 2-3 T cells / hpf in PDAC 1 • T cell tumor i
Slide 21: AMPLIFY-201: Clinical Data Summary
AMPLIFY-201: Clinical Data Summary ELI-002 monotherapy generates robust immune response that correlates with clinical benefit Well Tolerated No Dose • No Grade 3/4 TEAEs, no CRS, No DLTs; 11/25 (44%) had Grade 1 or 2 AEs Limiting Toxicity • Significant reduction in risk of progression or death with
Slide 22: ELI-002 Differentiation
ELI-002 Differentiation* Distinct clinical and operational advantages over comparable cancer vaccines Exclusively Anti-Tumor Clinical Programs Lymph Node Targeting KRAS “Off-the-Shelf” Immune Responses In Early Disease Engagement Mutations Neoantigen Vaccines ELI-002 7 Shared KRAS SLATE- KRAS - - 4
Slide 23: Continuing Execution Momentum into 2024
Continuing Execution Momentum into 2024 2023 Accomplishments 2024 Anticipated Milestones AMPLIFY-201 Completed Phase 1a enrollment AMPLIFY-201 Updated Clinical data (1Q-2024) AMPLIFY-7P Initiated Phase 1a study AMPLIFY-7P PDAC Phase 2 Initiation (1Q-2024) AMPLIFY-201 Presented Preliminary
Slide 24: Targeting the Lymph Nodes to AMPlify Immunotherapy
Targeting the Lymph Nodes to AMPlify Immunotherapy January 2024
Elicio Therapeutics — Investor Presentation (January 2024) on 6ix